Industry

SignaBlok Receives Orphan Drug Designation From FDA for a First-in-Class TREM-1 Peptide Inhibitor for the Treatment of Retinopathy of Prematurity

Eyewire+6d ago2 min read

Key Takeaways The FDA granted Orphan Drug Designation to SignaBlok’s triggering receptor expressed on myeloid cells 1 peptide inhibitor for treating retinopathy of prematurity According to the company, the designation highlights the therapy’s potential as a first-in-class, macrophage-targeted approach Orphan status provides development incentives, including tax credits, fee exemptions, and potential 7-year market exclusivity upon FDA approval SignaBlok announced that the FDA has granted Orphan Drug Designation to the company’s triggering receptor expressed on myeloid cells 1 (TREM-1) peptide inhibitor for the treatment of retinopathy of prematurity (ROP). “Orphan Drug Designation for ROP represents a significant milestone in the development of our TREM-1 therapy for the treatment of ROP,” said Alexander B. Sigalov, PhD, president and founder of SignaBlok. “This decision by the FDA recognizes the potential for a first-in-class, macrophage-targeted TREM-1 peptide inhibitor to address a high unmet need for preterm infants suffering from ROP. We are very encouraged by favorable preclinical efficacy, pharmacokinetic, and tolerability data in clinically relevant animal models. These data will be presented at the 2026 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) to be held in Denver, Colorado, May 3 to 7, 2026.” The FDA's Orphan Drug Designation program provides orphan status to drugs defined as those intended for the safe and effective treatment, diagnosis, or prevention of rare diseases that affect fewer than 200,000 people in the United States. Orphan Drug Designation qualifies the sponsor of the drug for certain development incentives, including tax credits for qualified clinical testing, prescription drug user fee exemptions, and 7-year marketing exclusivity upon FDA approval.

Read full article on Eyewire+

AI Summary

Quick Take

The FDA has granted Orphan Drug Designation to SignaBlok’s TREM-1 peptide inhibitor, a first-in-class macrophage-targeted therapy for the treatment of retinopathy of prematurity (ROP). This regulatory milestone follows encouraging preclinical data demonstrating favorable efficacy and safety in animal models, signaling a novel approach to preventing blindness in preterm infants.

Why It Matters

Managing ROP remains a delicate balance between treating aggressive neovascularization and minimizing the systemic or ocular side effects of current interventions like laser therapy or anti-VEGF injections. By targeting the triggering receptor expressed on myeloid cells 1 (TREM-1), this therapy aims to modulate the inflammatory environment via macrophages rather than simply blocking growth factors. This represents a significant shift in ROP research, potentially offering a more precise tool for a high-risk pediatric population where long-term developmental safety is paramount.

Key Details

The therapy is a first-in-class peptide inhibitor targeting the triggering receptor expressed on myeloid cells 1 (TREM-1).
Orphan Drug Designation provides SignaBlok with development incentives, including tax credits for clinical testing and exemptions from prescription drug user fees.
Upon potential FDA approval, the designation grants the company seven years of market exclusivity for the ROP indication.
Preclinical data indicates the inhibitor has favorable pharmacokinetics and tolerability in clinically relevant animal models.
The FDA's Orphan Drug program is reserved for treatments targeting diseases affecting fewer than 200,000 people in the U.S.

Practice Implications

Clinicians should note this as an emerging therapeutic class that moves beyond VEGF inhibition toward immunomodulation in the retina. While still in early development, a macrophage-targeted approach could eventually provide an alternative for infants who are poor candidates for current standard-of-care treatments or those at risk for anti-VEGF-related developmental concerns.

Who's Affected

Pediatric OphthalmologistsRetina SpecialistsNeonatologistsPediatric Optometrists

What's Next

SignaBlok is scheduled to present comprehensive preclinical efficacy and pharmacokinetic data at the ARVO 2026 annual meeting in Denver. Future developments will focus on transitioning these animal model findings into phase 1 clinical trials to assess safety in human neonates.

Evidence StrengthPreliminary

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.